Details for Patent: 8,734,847

Which drugs does patent 8,734,847 protect, and when does it expire?

Patent 8,734,847 protects TIVORBEX and is included in one NDA.

This patent has thirty-seven patent family members in twenty-one countries.

Summary for Patent: 8,734,847

Title:	Formulation of indomethacin
Abstract:	The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
Inventor(s):	Dodd; Aaron (Nedlands, AU), Meiser; Felix (Claremont, AU), Norret; Marck (Darlington, AU), Russell; Adrian (Rivervale, AU), Bosch; H William (Bryn Mawr, PA)
Assignee:	Iceutica Py Ltd. (Philadelphia, PA)
Application Number:	13/776,536
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,734,847

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-001	Feb 24, 2014		DISCN	Yes	No			Y
Genus	TIVORBEX	indomethacin	CAPSULE;ORAL	204768-002	Feb 24, 2014		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 8,734,847

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	2009901745	Apr 24, 2009

International Family Members for US Patent 8,734,847

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3628
Australia	2010239081
Australia	2014202776
Australia	2016200397
Brazil	PI1014275